Envista (NYSE:NVST) will be releasing its earnings data after the market closes on Tuesday, August 3rd. Analysts expect Envista to post earnings of $0.44 per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.
Envista (NYSE:NVST) last announced its earnings results on Wednesday, May 5th. The company reported $0.54 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.23. Envista had a return on equity of 6.93% and a net margin of 5.00%. The company had revenue of $709.20 million for the quarter, compared to analyst estimates of $636.89 million. On average, analysts expect Envista to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Envista stock opened at $41.77 on Tuesday. The company has a current ratio of 1.02, a quick ratio of 0.77 and a debt-to-equity ratio of 0.24. The company’s 50-day moving average price is $43.09. The stock has a market cap of $6.72 billion, a P/E ratio of 61.43, a PEG ratio of 0.84 and a beta of 1.93. Envista has a fifty-two week low of $20.97 and a fifty-two week high of $46.52.
In related news, SVP Jeffrey Kappler sold 1,717 shares of the company’s stock in a transaction dated Friday, July 16th. The stock was sold at an average price of $42.00, for a total value of $72,114.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Mischa Reis sold 1,049 shares of the company’s stock in a transaction dated Monday, May 3rd. The stock was sold at an average price of $43.73, for a total value of $45,872.77. Following the completion of the transaction, the senior vice president now directly owns 49,159 shares of the company’s stock, valued at approximately $2,149,723.07. The disclosure for this sale can be found here. Insiders sold 75,911 shares of company stock worth $3,362,955 in the last 90 days. Company insiders own 0.82% of the company’s stock.
Several research firms have weighed in on NVST. Credit Suisse Group boosted their price target on Envista from $49.00 to $55.00 and gave the company an “outperform” rating in a research note on Thursday, May 6th. Morgan Stanley boosted their price target on Envista from $42.00 to $46.00 and gave the company an “equal weight” rating in a research note on Friday, May 7th. Zacks Investment Research upgraded Envista from a “hold” rating to a “strong-buy” rating and set a $52.00 price target on the stock in a research note on Saturday, May 8th. Piper Sandler boosted their price target on Envista from $41.00 to $45.00 and gave the company a “neutral” rating in a research note on Thursday, May 6th. Finally, TheStreet upgraded Envista from a “d+” rating to a “c” rating in a research note on Thursday, May 13th. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. Envista has a consensus rating of “Buy” and a consensus target price of $43.33.
Envista Company Profile
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, and markets dental products in the United States and internationally. The company operates in two segments, Specialty Products & Technologies and Equipment & Consumables. The company’s Specialty Products & Technologies segment provides dental implant systems, guided surgery systems, biomaterials, prefabricated and custom-built prosthetics, and dental eye loupes to oral surgeons, prosthodontists, and periodontists under the brands, including Nobel Biocare, Alpha Bio Tec, Implant Direct, Logon, Nobel Procera, and Orascoptic; and brackets and wires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products under the Damon, Ormco, Insignia, AOA, and Spark brands.
Featured Article: 52-Week High/Low Prices For Stock Selection
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: Earnings Per Share (EPS) Explained
7 Bellwether Stocks Signaling a Return to Normal
Bellwether stocks are considered to be leading indicators about the direction of the overall economy, a specific sector, or the broader market. They are predictive stocks in that investors can use the company’s earnings reports to gauge economic strength or weakness.
The traditional definition of bellwether stocks brings to mind established, blue-chip companies. They are the home of mature brands with consumer loyalty. These may be stocks that aren’t associated with exceptional growth; some may be dividend stocks.
But there’s something different about normal this time around. If it’s true (and I think it is) that the old rules no longer apply, investors need to change the way they think about bellwether stocks. Plus, let’s face it, many stocks that we might consider to be bellwether stocks have already had a bit of a vaccine rally. That means that the easy gains are gone.
With that in mind, we’ve put together this special presentation that highlights seven of what may be termed the new bellwether stocks. These are stocks that investors should be paying attention to as the economy continues to reopen.
One quality of many of these stocks is that they are either negative for 2021 or underperforming the broader market. And that means that they are likely to have a strong upside as the economy grows.
View the “7 Bellwether Stocks Signaling a Return to Normal”.
Discussion about this post